作者
Joseph D Szustakowski, Suganthi Balasubramanian, Erika Kvikstad, Shareef Khalid, Paola G Bronson, Ariella Sasson, Emily Wong, Daren Liu, J Wade Davis, Carolina Haefliger, A Katrina Loomis, Rajesh Mikkilineni, Hyun Ji Noh, Samir Wadhawan, Xiaodong Bai, Alicia Hawes, Olga Krasheninina, Ricardo Ulloa, Alex E Lopez, Erin N Smith, Jeffrey F Waring, Christopher D Whelan, Ellen A Tsai, John D Overton, William J Salerno, Howard Jacob, Sandor Szalma, Heiko Runz, Gregory Hinkle, Paul Nioi, Slavé Petrovski, Melissa R Miller, Aris Baras, Lyndon J Mitnaul, Jeffrey G Reid
发表日期
2021/7
来源
Nature genetics
卷号
53
期号
7
页码范围
942-948
出版商
Nature Publishing Group US
简介
The UK Biobank Exome Sequencing Consortium (UKB-ESC) is a private–public partnership between the UK Biobank (UKB) and eight biopharmaceutical companies that will complete the sequencing of exomes for all ~500,000 UKB participants. Here, we describe the early results from ~200,000 UKB participants and the features of this project that enabled its success. The biopharmaceutical industry has increasingly used human genetics to improve success in drug discovery. Recognizing the need for large-scale human genetics data, as well as the unique value of the data access and contribution terms of the UKB, the UKB-ESC was formed. As a result, exome data from 200,643 UKB enrollees are now available. These data include ~10 million exonic variants—a rich resource of rare coding variation that is particularly valuable for drug discovery. The UKB-ESC precompetitive collaboration has further …
学术搜索中的文章
JD Szustakowski, S Balasubramanian, E Kvikstad… - Nature genetics, 2021